Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting-Reference-Cited by-同舟云学术

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

Published:2017-06-23 Issue:6 Volume:12 Page:e0178420
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Abernethy Amy P.,Arunachalam Ashwini,Burke Thomas,McKay Caroline,Cao Xiting,Sorg Rachael,Carbone David P.

Funder

Merck & Co.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Surveillance Epidemiology and End Results (SEER) Program: SEER Cancer Statistics Review (CSR) 1975–2012 (updated August 20, 2015);N Howlader,2015

2. Lung cancer;RS Herbst;N Engl J Med,2008

3. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer, 2015. http://seer.cancer.gov/statfacts/html/lungb.html

4. NCCN Guidelines: Non-small cell lung cancer version 7.2015, 2015. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

5. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update;GA Masters;J Clin Oncol,2015

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

2. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;Clinical Lung Cancer;2024-09

3. Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC;JAMA Network Open;2024-08-19

4. Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer;Immunotherapy;2024-03-15

5. Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations;ESMO Real World Data and Digital Oncology;2024-03